During the past decade, Centro Oncologico Riojano Integral (Cori) conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 19 clinical trials were completed, i.e. on average, 65.5% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 16 clinical trials were completed. i.e. 145.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Oncologico Riojano Integral (Cori)" #1 sponsor was "Hoffmann-La Roche" with 22 trials, followed by "EMD Serono Research & Development Institute, Inc." with 4 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Oncologico Riojano Integral (Cori)" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Centro Oncologico Riojano Integral (Cori)" are "Breast Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Cervical Cancer" (2 trials), "Early Breast Cancer" (2 trials) and "Gastric Cancer" (2 trials). Many other conditions were trialed in "Centro Oncologico Riojano Integral (Cori)" in a lesser frequency.

Most popular intervention types in "Centro Oncologico Riojano Integral (Cori)" are "Drug" (34 trials), "Other" (4 trials), "Biological" (3 trials), "Radiation" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (10 trials), "Atezolizumab" (8 trials), "Placebo" (8 trials), "Carboplatin" (5 trials) and "Bevacizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Centro Oncologico Riojano Integral (Cori)" are 30 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Centro Oncologico Riojano Integral (Cori)". undefined are not yet recruiting, 7 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Centro Oncologico Riojano Integral (Cori), undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Oncologico Riojano Integral (Cori), 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".